Journal of Substance Abuse Treatment
Volume 36, Issue 3 , Pages 244-251 , April 2009

Factors affecting willingness to provide buprenorphine treatment

  • Julie Netherland, M.S.W.

      Affiliations

    • The New York Academy of Medicine, Division of Health Policy, New York, NY, 10029, USA
    • Corresponding Author InformationCorresponding author. The New York Academy of Medicine, Division of Health Policy, 1216 5th Ave., New York, NY, 10029, USA. Tel.: +1 212 419 3560; fax: +1 212 876 4220.
    • ,
  • Michael Botsko, M.S.W.

      Affiliations

    • The New York Academy of Medicine, Center for Urban Epidemiologic Studies, New York, NY, 10029, USA
    • ,
  • James E. Egan, M.P.H.

      Affiliations

    • The New York Academy of Medicine, Center for Urban Epidemiologic Studies, New York, NY, 10029, USA
    • ,
  • Andrew J. Saxon, M.D.

      Affiliations

    • Addictions Care Line VA Puget Sound Health Care System and The Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98108, USA
    • ,
  • Chinazo O. Cunningham, M.S., M.D.

      Affiliations

    • Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 10467, USA
    • ,
  • Ruth Finkelstein, Sc.D.

      Affiliations

    • The New York Academy of Medicine, Division of Health Policy, New York, NY, 10029, USA
    • ,
  • Mark N. Gourevitch, M.D., M.P.H.

      Affiliations

    • Division of General Internal Medicine, New York University School of Medicine, New York, NY, 10016, USA
    • ,
  • John A. Renner, M.D.

      Affiliations

    • Boston University School of Medicine, Boston, MA, 02118, USA
    • VA Boston Healthcare System, Boston, MA, 02152, USA
    • ,
  • Nancy Sohler, Ph.D., M.P.H.

      Affiliations

    • Sophie Davis School of Biomedical Education, City University of New York, City College Campus, 160 Convent Avenue, New York, NY, 10031,USA
    • ,
  • Lynn E. Sullivan, M.D.

      Affiliations

    • Yale University School of Medicine, New Haven, CT, 06520, USA
    • ,
  • Linda Weiss, Ph.D.

      Affiliations

    • The New York Academy of Medicine, Center for Urban Epidemiologic Studies, New York, NY, 10029, USA
    • ,
  • David A. Fiellin, M.D.

      Affiliations

    • Yale University School of Medicine, New Haven, CT, 06520, USA
    • ,
  • the BHIVES Collaborative

      Affiliations

    • Collaborative. Yale University School of Medicine (New Haven, CT), El Rio Santa Cruz Neighborhood Health Center (Tucson, AZ), OASIS (Oakland, CA), Oregon Health & Sciences University (Portland, OR), Montefiore Medical Center (New York, NY), University of Miami Medical School (Miami, FL), Miriam Hospital (Providence, RI), UCSF Positive Health Program (San Francisco, CA), Johns Hopkins University (Baltimore, MD), CORE Center (Chicago, IL).

Received 18 January 2008 ,Revised 19 May 2008 ,Accepted 22 June 2008.

References 

  1. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction: Effective medical treatment of opiate addiction. Journal of the American Medical Association. 1998;280:1936–1943
  2. Becker WC, Fiellin DA. Provider satisfaction with office-based treatment of opioid dependence a systematic review. Substance Abuse. 2006;26:15–22
  3. Cunningham CO, Sohler NL, et al. Attending physicians' and residents' attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Family Medicine. 2006;38:336–340
  4. Elliott V. Link between primary care, addiction services may help treatment. amednews.com2001;
  5. Fiellin D. The first three years of buprenorphine in the U.S.: Experience to date and future directions. Journal of Addictive Medicine. 2007;1:62–67
  6. Fiellin DA, Barthwell AG. Guideline development for office-based pharmacotherapies for opoid dependence. Journal of Addictive disorders. 2003;22:109–120
  7. Fiellin DA, Butler R, et al. The physician's role in caring for patients with substance use disorders: Implications for medical education and training. Substance Abuse. 2002;23:207–222
  8. Fiellin DA, Kleber H, et al. Consensus statement on office-based treatment of opioid dependence using buprenorphine. Journal of Substance Abuse Treatment. 2004;27:153–159
  9. Fiellin DA, O'Connor P. New federal initiatives to enhance the medical treatment of opioid dependence. Annals of Internal Medicine. 2002;137:688–692
  10. Fiellin DA, O'Connor PG, et al. Methadone maintenance in primary care: A randomized controlled trial. Journal of the American Medical Association. 2001;286:1724–1731
  11. Fiellin DA, Pantalon MV, et al. Treatment of heroin dependence with buprenorphine in primary care. American Journal of Drug and Alcohol Abuse. 2002;28:231–241
  12. Fiellin DA, Rosenheck RA, et al. Office-based treatment for opioid dependence: Reaching new patient populations. American Journal of Psychiatry. 2001;158:1200–1204
  13. Friedman SR, Curtis R, et al. Social networks, drug injectors's lives, and HIV/AIDS. New York: Kluwer Academic/Plenum Publishers; 1999;
  14. Friedmann P, McCullough D, et al. Screening and intervention for illicit drug abuse: A national survey of primary care physicians and psychiatrists. Archives of Internal Medicine. 2001;161:248–251
  15. Gibson AE, Doran CM, et al. A comparison of buprenorphine treatment in clinic and primary care settings: A randomised trial. Medical Journal of Australia. 2003;179:38–42
  16. Godden T, Byrne A, et al. Care and shared care of opiate misusers by general practitioners in inner London. Journal of Substance Misuse Nursing, Health & Social Care. 1997;2:217–221
  17. Gossop M, Marsden J, et al. Methadone treatment practices and outcome for opiate addicts treated in drug clinics and in general practice: Results from the National Treatment Outcome Research Study. British Journal of General Practice. 1999;49:31–34
  18. Hser YI, Hoffman V, et al. A 33-year follow-up of narcotics addicts. Archives of General Psychiatry. 2001;58:503–508
  19. Join Together . National poll of physicians finds barriers to widespread buprenorphine use. Boston, MA: Join Together, Boston University School of Public Health; 2003;
  20. Keen J, Oliver P, et al. Does methadone maintenance treatment based on the new national guidelines work in a primary care setting?. British Journal of General Practice. 2003;53:461–467
  21. King VL, Stoller KB, et al. A multicenter randomized evaluation of methadone medical maintenance. Drug and Alcohol Dependence. 2002;65:137–148
  22. Kissin W, McLeod C, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. Journal of Addictive Disease. 2006;25:91–103
  23. Knudsen HK, Ducharme LJ, et al. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence. 2006;164–174
  24. Knudsen HK, Ducharme LJ, et al. Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment. 2006;30:363–373
  25. Laine C, Hauck WW, et al. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. Journal of the American Medical Association. 2001;285:2355–2362
  26. Merrill JO, Rhodes LA, et al. Mutual mistrust in the medical care of drug users: The keys to the “narc” cabinet. Journal of General Internal Medicine. 2002;17:327–333
  27. Novick DM, Joseph H. Medical maintenance: The treatment of chronic opiate dependence in general medical practice. Journal of Substance Abuse Treatment. 1991;8:233–239
  28. Novick DM, Joseph H, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): Follow-up at three and a half to nine and a fourth years. Journal of General Internal Medicine. 1994;9:127–130
  29. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Annals of Internal Medicine. 2000;133:40–54
  30. O'Connor PG, Oliveto AH, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. American Journal of Medicine. 1998;105:100–105
  31. O'Connor PG, Samet JH. The substance-using human immunodeficiency virus patient: Approaches to outpatient management. American Journal of Medicine. 1996;101:435–444
  32. Rhoades H, Creson D, et al. Retention, HIV risk and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health. 1998;88:34–39
  33. Renner J. Education status report: Success and challenges. In: Presented at the Buprenorphine Summit, February 21, 2008, Washington, D.C.. 2008;
  34. Robertson JR, Ronald PJ, et al. Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years. BMJ. 1994;309:369–372
  35. Rogers , Everett M. Diffusion of Innovations. 5th ed.. New York, NY: Free Press; 2003;
  36. Saitz R, Friedmann PD, et al. Professional satisfaction experienced when caring for substance-abusing patients: Faculty and resident physician perspectives. Journal of General Internal Medicine. 2002;17:373–376
  37. SAMHSA . Overview of findings from the 2003 National Survey on Drug Use and Health. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004;
  38. SAMHSA . National Household Survey on Drug Abuse. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2006;
  39. SAMHSA . Buprenorphine physician and treatment program locater. Available at http://buprenorphine.samhsa.gov/bwns_locator/dr_facilitylocatordoc.htm2008;(Accessed May 15, 2008)
  40. Saxon AJ, McCarty D. Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacology & Therapeutics. 2005;108:119–128
  41. Stanton A, McLeod C, et al. Expanding treatment of opioid dependence: Initial physician and patient experiences with the adoption of buprenorphine. Westat. 2006;Available at: http://www.buprenorphine.samhsa.gov/ASAM_06_Final_Results.pdf(Accessed May 15, 2008)
  42. Sullivan L, Tetrault J, et al. Training HIV physicians to prescribe buprenorphine for opioid dependence. Substance Abuse. 2006;27:11–16
  43. Sullivan LE, Fiellin DA. Buprenorphine: Its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clinical Infectious Diseases. 2005;41:891–896
  44. Turner BJ, Laine C, et al. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Archive of Internal Medicine. 2005;165:1769–1776
  45. Weinrich M, Stuart M. Provision of methadone treatment in primary care medical practices: Review of the Scottish experience and implications for US policy. Journal of the American Medical Association. 2000;283:1343–1348
  46. West JC, Kosten TR, et al. Challenges in increasing access to buprenorphine treatment for opiate addiction. American Journal on Addictions. 2004;13(Suppl 1):S8–S16
  47. Wilson P, Watson R, et al. Methadone maintenance in general practice: Patients, workload, and outcomes. BMJ. 1994;309:641–644

PII: S0740-5472(08)00100-1

doi: 10.1016/j.jsat.2008.06.006

Journal of Substance Abuse Treatment
Volume 36, Issue 3 , Pages 244-251 , April 2009

Article Tools

* Image Usage & Resolution